Author:
Krzyżanowska Małgorzata,Kozon Katarzyna,Olszewski Jakub,Patyra Andrzej
Abstract
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system and is associated with the presence of autoantibodies to anti–aquaporin-4 (AQP4-IgG). Interleukin-6 plays a key role in the pathogenesis of this disorder. Satralizumab, a humanized monoclonal antibody, targets the interleukin-6 receptor thus affects the course of the disease. In Poland, satralizumab treatment has been offered free of charge by the public health service since November 2021. The results of SAkura studies demonstrate the long terms efficacy of satralizumab and provide evidence that satralizumab reduces the risk of relapse in patients with aquaporin-4-immunoglobulin G (IgG)–seropositive (AQP4-IgG+) NMOSD.
Publisher
Warszawski Uniwersytet Medyczny
Reference28 articles.
1. Traboulsee, A., et al., Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol., 2020, 19(5), 402-412. doi:10.1016/s1474-4422(20)30078-8.
2. Shumway CL, Patel BC, De Jesus O. Neuromyelitis Optica (NMO, Devics Disease) [Updated 2023 Feb 12]. In: StatPearls. Treasure Island (FL): StatPearls Publishing
3. 2023 https://www.ncbi.nlm.nih.gov/books/NBK572108/ (data dostepu: 2023.08.14).
4. Zapalenie rdzenia i nerwów wzrokowych (zespół Devica, neuromyelitis optica). 2023; https://podyplomie.pl/wiedza/neurologia/188,zapalenie-rdzenia-i-nerwow-wzrokowych-zespol-devica-neuromyelitis-optica (data dostępu: 2023.08.14).
5. Seok, J.M., et al., Differentiation between multiple sclerosis and neuromyelitis optica spectrum disorder using a deep learning model. Sci. Rep. 2023, 13(1), 11625. doi:10.1038/s41598-023-38271-x.